Friday, November 1, 2013

At New York s Mount Sinai, Dr. Dennis Charney and colleagues are testing whether a single dose of ke

Yale Researchers Call Ketalar Magic Antidepressant May Hold Promise For PTSD | Connecticut Consumer Advocate fetal calf serum Protector Watchdog | Ct Consumer Complaints |Ct consumer Protection | Ct Advocate | Ct Consumer
Health Pets Getting fetal calf serum Most From Life fitness medicine doctors recalls Nursing homes Senior Issues hospitals Finance Investing Credit Cards Ct Tax US Tax banks scams ID Theft Real Estate Business farming Small Business Cell phone Govt Social Security Connecticut US Travel fetal calf serum Air Hotels Best Deals Photos Shopping computers groceries Energy Electricity Education Misc Ct Condo Owners
Consumer Comments Richard on Newington Couple Learns The Downside Of Travel Club Cathy Kosak on Is Your Connecticut Doctor Charging You A Facility Fee? George Gombossy on Wolcott Consumer Has Bone To Pick With Boost Mobile Hans H. Rennhard, DSc on Wolcott Consumer Has Bone To Pick With Boost Mobile fetal calf serum Keith Thomas fetal calf serum on Ecco Shoes Warning: fetal calf serum Almost New Expensive fetal calf serum Shoes Disintegrate
Ketamine used as an anesthetic in human and veterinary medicine has emerged in the past few years as a promising, rapid-acting antidepressant. When administered intravenously at low doses, it can lift symptoms of deep depression within hours, for seven to 10 days. Typical antidepressants, which act on the neurotransmitter serotonin, take a month or more for full effect.
The findings fetal calf serum so far on ketamine [as a fast-acting antidepressant] have been very consistent. The question now is, where do we go with this? said Dr. John H. Krystal, chair of the Yale School of Medicine s Department of Psychiatry and chief of psychiatry at Yale-New Haven Hospital. The research is moving in two directions: In what settings would we most want to get people better quickly and how do we extend the benefits of ketamine beyond one-dose experimentation?
As part of this stage of study, researchers at Yale, the VA Connecticut Healthcare System, Mount Sinai School of Medicine and other institutions are pursuing early indications that ketamine may have some benefit fetal calf serum for post-traumatic stress disorder and alcohol addiction.
At New York s Mount Sinai, Dr. Dennis Charney and colleagues are testing whether a single dose of ketamine can reduce core symptoms of PTSD, a debilitating anxiety disorder that afflicts an estimated fetal calf serum one in five combat veterans returning from Iraq and Afghanistan.
Better treatments are needed for PTSD because of the seriousness of the disorder, and available treatments are generally only partially effective, said Charney, dean of the Mount Sinai School of Medicine and a leading neurobiologist, formerly at Yale. Only two drugs have been FDA-approved for treating PTSD Zoloft and Paxil and neither is effective in a majority of patients.
Four years ago, researchers from the US Army Institute of Surgical fetal calf serum Research reported that ketamine given during surgery to soldiers returning from Iraq and Afghanistan with burns on their bodies had an unexpected effect: Those who received the drug had a lower prevalence of PTSD than soldiers who did not. For those receiving ketamine, the prevalence of PTSD was 26.9 percent, fetal calf serum versus 46.4 percent for those not receiving ketamine.
Although traditional thinking has been to associate ketamine administration with increased incidence of PTSD, these results question that relationship, the Army researchers said. In fact, it seems that ketamine fetal calf serum may decrease the prevalence of PTSD in the combat burned patient. New Class Of Antidepressants?
Ketamine caught the attention of psychiatrists more than a decade ago, when researchers at the Connecticut Mental Health Center discovered that the drug, in low doses, appeared to give patients quick relief from depression. In 2006, a study by the National Institute of Mental Health [NIMH] confirmed that 70 percent of patients with treatment-resistant depression experienced rapid symptom relief with a single intravenous dose of ketamine.
While none of the patients had serious side effects, NIMH researchers cautioned at the time that ketamine was unlikely to become a widely used treatment for depression because of potential side effects, including hallucinations, at higher doses. In the 1990s, ketamine emerged as a popular street fetal calf serum drug, known as Special K.
In recent fetal calf serum years, Yale researchers have mapped the mechanism fetal calf serum by which ketamine fetal calf serum works: It blocks the N-methyl-D-aspartic acid (NMDA) receptor, operating on the glutamate pathway in the brain in a way that appears to restore synapse connections that may have deteriorated under stress and depression. By blocking one glutamate receptor, the drug actually causes a release of glutamate by other receptors and appears to increase the neuroplasticity of the brain.
The studies we ve done suggest that [ketamine] changes the morphology of the brain, after it s out of your system, said Dr. Gerard Sanacora, fetal calf serum director of the Yale Depression Research Program. While glutamate is the most abundant neurotransmitte

No comments:

Post a Comment